{"entity":{"id":"nct05218408","kind":"trial","name":"CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type","aka":[],"tldr":"A phase 1/2 trial of CYNK-001 run by Celularity Incorporated, withdrawn before enrolling.","summary":"CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type is a phase 1/2 interventional study registered as NCT05218408 by Celularity Incorporated, started 2021-09. Conditions recorded: Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma and Glioblastoma Multiforme. Interventions recorded: CYNK-001 systemic and Intra cavity administration.","status":"withdrawn","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05218408","url":"https://clinicaltrials.gov/study/NCT05218408"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cynk-001"],"companies":["celularity"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05218408","phase":"1/2","setting":"A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma","sponsor":"Celularity Incorporated","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05218408/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"cynk-001","kind":"drug","name":"CYNK-001","route":"/drugs/cynk-001/"}],"company":[{"id":"celularity","kind":"company","name":"Celularity","route":"/companies/celularity/"}]}}